Description

Efgartigimod alfa is a neonatal Fc receptor (FcRn) antagonist, designed to reduce pathogenic IgG antibody levels. It’s widely researched in autoimmune disorders, such as myasthenia gravis, immune thrombocytopenia (ITP), and pemphigus vulgaris.

This subcutaneous injectable formulation contains 400mg of efgartigimod in a 5.6ml solution. Manufactured by Patheon Italia S.p.A., and approved in China under NMPA SJ20240029 with product code 86984816000020.

?? For laboratory research only. Not for clinical, diagnostic, or veterinary use.

Product Specifications

Mechanism & Research Applications

Efgartigimod alfa binds to neonatal Fc receptor (FcRn), interfering with IgG recycling. This leads to increased degradation of circulating pathogenic IgG antibodies — a novel therapeutic mechanism in autoimmune disease research.

Common Research Areas:

• Myasthenia gravis models

• Pemphigus and ITP immunopathology

• FcRn-mediated IgG homeostasis

• IgG turnover and half-life studies

• Fc fusion protein therapeutics

Side Effects (Observed in Research Models)

• Mild injection site reactions

• Transient headache or fatigue

• Increased risk of infections under prolonged exposure

• Transient leukopenia in rodent models

• Gastrointestinal disturbances in higher dosing

Ensure all use complies with animal ethics and safety standards.

Safety & Handling

• Use Restriction: Laboratory research use only

• PPE: Gloves, lab coat, goggles required

• Storage: Refrigerate (2–8°C), do not freeze

• Disposal: Follow chemical and biological waste protocols

Core Keywords

Efgartigimod Alfa injection, FcRn blocker research, 400mg efgartigimod vial, autoimmune IgG inhibitor, Patheon Italia biologics, NMPA SJ20240029, lab-grade efgartigimod, wholesale research antibody modulators

Research Use Disclaimer

This product is for experimental research use only. Not for use in humans or animals. Misuse may lead to regulatory or health risks. Always follow institutional biosafety procedures.